BANDEAU	TUTELLES	
L’unité	de	recherche	de	l’institut	du	thorax	
Inserm	UMR	1087	/	CNRS	UMR	6291	
Nantes,	France	
3D innovative hiPSC-based models including the
microenvironment
for phenotypic screening - Application on metabolic
diseases
Karim	Si-Tayeb	
ELRIGfr	Conference	23/24	mai	2018	Le	Bischenberg,	Bischoffsheim,	France
2	
Familial hypercholesterolemia (FH)
Facteurs	de	risque	génétique	
Récepteur	
LDL	
Inconnus	
APOB	
PCSK9	
Hypercholesterolemia:	
Impaired	LDL-cholesterol	uptake	
Modified	from	Norata	et	al.	EHJ	2013	
Identification	of	informative	famillies	displaying:	
	
-  A	spontaneously	low	LDL-C	level	(FHBL)	
-  A	hypercolesterolemia	without	cardiovascular	disease	
(CIC	Thorax,	Matthieu	Pichelin,	Marie	Marrec)	
	
Absence	of	mutations	in	known	genes	involved	in	FH	
(LDLR,	PCSK9,	APOB,	ANGPTL3)	
(Jocelyne	Magré,	Jean-Jacques	Schott)
3	
The	Scientist	Magazine	
April	2016	
Si-Tayeb et al. Disease Models & Mechanisms 2016
Patient
Urine-derived cells
hiPS cells
in vitro study of familial hypercholesterolemia
Hepatocytes
© l’institut du thorax
Modeling FH in vitro from an urine sample - the power of hiPS cells
4	
From hiPS cells toward hepatocytes – back to
developmental biology
He:	precardiac	mesoderm	
End:	endoderm	
Lb:	liver	bud	
E:	endothelial	cells	
STM:	Septum	transversum	
	d0	 d5	 d10	 d15	 d20	
Hepatocytes	
Definitif	
Endoderm	
Hepatic	
progenitors	
Specified	
Definitif	
Endoderm	
Human	
pluripotent	
stem	cells	
Si-Tayeb	et	al.	Developmental	Cell	2010	
Si-Tayeb	et	al.	Hepatology	2010
5	
Fluorescent LDL uptake analyzed by flow cytometry
Phenotype	
reproduced	in	vitro	
Familial hypercholesterolemia in a petri-dish
Phenotype	
pharmacologicaly	
reversed	in	vitro	
Si-Tayeb,	Idriss	et	al.	Disease	Models	&	Mechanims	2016
Hypercholestérolémie:	
Défaut	d’internalisation	du	LDL-choléstérol
7	
A promising model that needs further maturation by adding a third dimension
Nature	review	2004
8	
Liver	
A promising model that needs further maturation by adding a third dimension
Amandine	Caillaud	Méryl	Roudaut
9	
A new differentiation protocol for a new environment
Cytokines
	d0	 d5	 d10	 d15	 d20	
Hepatocytes	
Definitif	
Endoderm	
Hepatic	
progenitors	
Specified	
Definitif	
Endoderm	
Human	
pluripotent	
stem	cells	
Méryl	Roudaut
10	
CYP450 basal activities and induction
CYP450	2C9	(ibuprofen)	
Diclofenac	->	4OH-Diclofenac		
CYP450	1A2	(caffein)	
Phenacetin->	Acetaminophen	
CYP450	2A6	
Nicotine->	Cotinine	
CYP450	2E1	(ethanol)	
Chlorzoxazone->	6-0H-Chlorzoxazone	
Méryl	Roudaut	
(nM)
(nM)
(nM)(nM)
11	
CYP450 basal activities and induction
CYP450	3A4	
Testosteron->	6ß-OH-testosteron	
0
100
200
300
400
500
0 10 20 30 40 50 60 70
nmol/L
Minutes
CYP3A4 activity (nmol/L/min/well)
Basal activity
Induced activity
0
50
100
150
200
250
Basal activity Induced activityActivitypercentage
CYP3A4 activity
*	
Méryl	Roudaut	
(nM)
12	
Conclusion and perspectives
hiPS	cells	 	->	Genetic	variability	
Hepatic	cells 	->	Phenotypic	screening	
3D	
2D	
6	puits	 96	puits
13	
Conclusion and perspectives
Liver	 NASH	 Fibrosis
www.umr1087@univ-nantes.fr	
L’unité	de	recherche	de	l’institut	du	thorax			
Inserm	UMR	1087	/	CNRS	UMR	6291	
Nantes,	France	
		Daniel	Buren	et	Patrick	Bouchain,	Les	Anneaux,	Quai	des	
Antilles,	Nantes,	création	pérenne	Estuaire	2007	©	Martin	
Argyroglo/LVAN		
L’institut du thorax
CARIOU Bertrand
LE MAY Cédric
MAGRE Jocelyne
PRIEUR Xavier
PICHELIN Matthieu
ARNAUD Lucie
AYER Audrey
BLANCHARD Claire
Wargny Matthieu
MOREAU François
CHADEUF Gilliane
DIJK Wienecke
THEDREZ Aurélie
SI-TAYEB Karim
IDRISS Salam
CAILLAUD Amandine
GIRARDEAU Aurore
ROUDAUT Méryl
CANTAT Pierre-Alexandre
LORANT Victoria
HCS Pharma
MAUBON Nathalie
MAUBON Gregory
SOUGUIR Zied
VANDENHAUTE Elodie

3D innovative hiPSC-based models including the microenvironment for phenotypic screening - Application on metabolic diseases